MX2022007669A - Composiciones y metodos para modular simultaneamente la expresion de genes. - Google Patents
Composiciones y metodos para modular simultaneamente la expresion de genes.Info
- Publication number
- MX2022007669A MX2022007669A MX2022007669A MX2022007669A MX2022007669A MX 2022007669 A MX2022007669 A MX 2022007669A MX 2022007669 A MX2022007669 A MX 2022007669A MX 2022007669 A MX2022007669 A MX 2022007669A MX 2022007669 A MX2022007669 A MX 2022007669A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- genes
- modulating expression
- methods
- simultaneously modulating
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 108020004459 Small interfering RNA Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
La presente invención se refiere a composiciones de constructos de ácido polinucleico recombinante que comprenden al menos una secuencia de ácido nucleico que codifica un ARNip capaz de unirse a un ARNm objetivo y al menos una secuencia de ácido nucleico que codifica un gen de interés; también se describe en la presente el uso de las composiciones en el tratamiento de una enfermedad o afección y en la modulación simultánea de la expresión de dos o más genes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19219276 | 2019-12-23 | ||
US202063042890P | 2020-06-23 | 2020-06-23 | |
PCT/IB2020/001091 WO2021130537A2 (en) | 2019-12-23 | 2020-12-21 | Compositions and methods for simultaneously modulating expression of genes |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022007669A true MX2022007669A (es) | 2022-07-19 |
Family
ID=74505291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022007669A MX2022007669A (es) | 2019-12-23 | 2020-12-21 | Composiciones y metodos para modular simultaneamente la expresion de genes. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220389423A1 (es) |
EP (1) | EP4081640A2 (es) |
JP (1) | JP2023507501A (es) |
KR (1) | KR20220121844A (es) |
CN (1) | CN114901822A (es) |
AU (1) | AU2020414441A1 (es) |
BR (1) | BR112022012324A2 (es) |
CA (1) | CA3159809A1 (es) |
CO (1) | CO2022010342A2 (es) |
IL (1) | IL294132A (es) |
MX (1) | MX2022007669A (es) |
PE (1) | PE20230430A1 (es) |
TW (1) | TW202136512A (es) |
WO (1) | WO2021130537A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3192949A1 (en) * | 2020-10-05 | 2022-04-14 | Justin Antony Selvaraj | Compositions and methods for simultaneously modulating expression of genes |
CA3213977A1 (en) * | 2021-04-19 | 2022-10-27 | Klaas Peter ZUIDEVELD | Method of treating lower urinary tract symptoms |
BR112023026961A2 (pt) * | 2021-06-23 | 2024-03-12 | Versameb Ag | Composições e métodos para modular a expressão de genes |
WO2023164708A1 (en) * | 2022-02-25 | 2023-08-31 | University Of South Florida | Design and development of a novel messenger rna therapeutic to treat atherosclerosis |
CN115948544B (zh) * | 2023-03-08 | 2023-05-16 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | Cited4和/或metrn在椎间盘退变程度的鉴别诊断中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004096852A1 (fr) | 2003-04-25 | 2004-11-11 | The Institute Of Microbiology And Epidemiology, Academy Of Military Medical Sciemces, Pla | Interferon$g(v) humain recombinant, son procede d'expression et ses utilisations |
AU2005231476B2 (en) | 2004-04-02 | 2011-09-01 | Zymogenetics, Inc. | Il-28 and il-29 cysteine mutants for treating viral infection |
WO2019079240A1 (en) * | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
-
2020
- 2020-12-21 BR BR112022012324A patent/BR112022012324A2/pt unknown
- 2020-12-21 CA CA3159809A patent/CA3159809A1/en active Pending
- 2020-12-21 CN CN202080089481.1A patent/CN114901822A/zh active Pending
- 2020-12-21 PE PE2022001165A patent/PE20230430A1/es unknown
- 2020-12-21 AU AU2020414441A patent/AU2020414441A1/en active Pending
- 2020-12-21 JP JP2022538076A patent/JP2023507501A/ja active Pending
- 2020-12-21 IL IL294132A patent/IL294132A/en unknown
- 2020-12-21 KR KR1020227025269A patent/KR20220121844A/ko unknown
- 2020-12-21 MX MX2022007669A patent/MX2022007669A/es unknown
- 2020-12-21 WO PCT/IB2020/001091 patent/WO2021130537A2/en unknown
- 2020-12-21 EP EP20848964.1A patent/EP4081640A2/en active Pending
- 2020-12-23 TW TW109145741A patent/TW202136512A/zh unknown
-
2022
- 2022-06-22 US US17/846,288 patent/US20220389423A1/en active Pending
- 2022-07-22 CO CONC2022/0010342A patent/CO2022010342A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2022010342A2 (es) | 2022-08-09 |
JP2023507501A (ja) | 2023-02-22 |
CA3159809A1 (en) | 2021-07-01 |
AU2020414441A1 (en) | 2022-08-18 |
WO2021130537A3 (en) | 2021-08-12 |
BR112022012324A2 (pt) | 2022-10-11 |
PE20230430A1 (es) | 2023-03-08 |
US20220389423A1 (en) | 2022-12-08 |
EP4081640A2 (en) | 2022-11-02 |
KR20220121844A (ko) | 2022-09-01 |
TW202136512A (zh) | 2021-10-01 |
IL294132A (en) | 2022-08-01 |
CN114901822A (zh) | 2022-08-12 |
WO2021130537A2 (en) | 2021-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022007669A (es) | Composiciones y metodos para modular simultaneamente la expresion de genes. | |
MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
PH12020551744A1 (en) | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues | |
WO2016106406A3 (en) | Rna agents for gst-pi gene modulation | |
MX2020001198A (es) | Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos. | |
CR20220136A (es) | Proteínas de fijación multiespecíficas para tratamiento contra el cáncer | |
EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
MX2022015079A (es) | Variantes de hsd17b13 y usos de las mismas. | |
MX2021006745A (es) | Constructos de iarn modificados quimicamente y usos de estos. | |
WO2015155686A3 (en) | Methods and compositions for rna-directed repression of transcription using crispr-associated genes | |
PH12021551135A1 (en) | Rna encoding a protein | |
PH12019500209A1 (en) | Methods and compositions for gene expression in plants | |
MX2022013945A (es) | Nuevas proteinas de union a repeticiones de anquirina y sus usos. | |
NZ752941A (en) | Frataxin expression constructs | |
MX2021014465A (es) | Construcciones de arni para inhibir la expresion de scap y metodos de uso de las mismas. | |
MX2022015169A (es) | Constructos de arni para inhibir la expresion de hsd17b13 y metodos de uso de los mismos. | |
MX2021006784A (es) | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de estos. | |
MX2021006253A (es) | Terapias génicas para enfermedad neurodegenerativa. | |
EA201691981A1 (ru) | Улучшенные транспортные молекулы модулярного антигена и их применение | |
MX2021005980A (es) | Adenovirus y metodos para usar adenovirus. | |
EP4249598A3 (en) | Hybrid promoters and their uses in therapy, notably for treating type ii collagenopathies | |
MX2023003925A (es) | Composiciones y metodos para modular simultaneamente la expresion de genes. | |
EA202190267A1 (ru) | Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака | |
BR112022002889A2 (pt) | Método para tratar distrofia muscular tendo como alvo o gene lama1 |